Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro

Authors

  • Maxim A.X. Tollenaere
  • Thomas Litman
  • Lena Moebus
  • Elke Rodriguez
  • Dora Stölzl
  • Katharina Drerup
  • Thomas Werfel
  • Jochen Schmitt
  • Hanne Norsgaard Skin Research, LEO Pharma A/S, DK-2750 Ballerup, Denmark
  • Stephan Weidinger

DOI:

https://doi.org/10.2340/00015555-3810

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345-360.

DOI: https://doi.org/10.1016/S0140-6736(20)31286-1

Wu J, Guttman-Yassky E. Efficacy of biologics in atopic dermatitis. Expert Opin Biol Ther 2020; 20: 525-538.

DOI: https://doi.org/10.1080/14712598.2020.1722998

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437-449.

DOI: https://doi.org/10.1111/bjd.19574

Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184: 450-463.

DOI: https://doi.org/10.1111/bjd.19573

Pavel AB, Zhou L, Diaz A, Ungar B, Dan J, He H, et al. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. J Am Acad Dermatol 2020; 82: 690-699.

DOI: https://doi.org/10.1016/j.jaad.2019.10.039

Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy 2020; 75: 54-62.

DOI: https://doi.org/10.1111/all.13954

Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol 2019; 139: 1480-1489.

DOI: https://doi.org/10.1016/j.jid.2018.12.018

Tsoi LC, Rodriguez E, Stolzl D, Wehkamp U, Sun J, Gerdes S, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol 2020; 145: 1406-1415.

DOI: https://doi.org/10.1016/j.jaci.2019.11.047

Mobus L, Rodriguez E, Harder I, Stolzl D, Boraczynski N, Gerdes S, et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol 2021; 147: 213-223.

DOI: https://doi.org/10.1016/j.jaci.2020.06.012

Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143: 155-172.

DOI: https://doi.org/10.1016/j.jaci.2018.08.022

Published

2021-04-29

How to Cite

Tollenaere, M. A., Litman, T., Moebus, L., Rodriguez, E., Stölzl, D., Drerup, K., Werfel, T., Schmitt, J., Norsgaard, H., & Weidinger, S. (2021). Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro. Acta Dermato-Venereologica, 101(4), adv00447. https://doi.org/10.2340/00015555-3810

Issue

Section

Short Communication

Categories